1,499 research outputs found
Representation learning of drug and disease terms for drug repositioning
Drug repositioning (DR) refers to identification of novel indications for the
approved drugs. The requirement of huge investment of time as well as money and
risk of failure in clinical trials have led to surge in interest in drug
repositioning. DR exploits two major aspects associated with drugs and
diseases: existence of similarity among drugs and among diseases due to their
shared involved genes or pathways or common biological effects. Existing
methods of identifying drug-disease association majorly rely on the information
available in the structured databases only. On the other hand, abundant
information available in form of free texts in biomedical research articles are
not being fully exploited. Word-embedding or obtaining vector representation of
words from a large corpora of free texts using neural network methods have been
shown to give significant performance for several natural language processing
tasks. In this work we propose a novel way of representation learning to obtain
features of drugs and diseases by combining complementary information available
in unstructured texts and structured datasets. Next we use matrix completion
approach on these feature vectors to learn projection matrix between drug and
disease vector spaces. The proposed method has shown competitive performance
with state-of-the-art methods. Further, the case studies on Alzheimer's and
Hypertension diseases have shown that the predicted associations are matching
with the existing knowledge.Comment: Accepted to appear in 3rd IEEE International Conference on
Cybernetics (Spl Session: Deep Learning for Prediction and Estimation
DHLP 1&2: Giraph based distributed label propagation algorithms on heterogeneous drug-related networks
Background and Objective: Heterogeneous complex networks are large graphs
consisting of different types of nodes and edges. The knowledge extraction from
these networks is complicated. Moreover, the scale of these networks is
steadily increasing. Thus, scalable methods are required. Methods: In this
paper, two distributed label propagation algorithms for heterogeneous networks,
namely DHLP-1 and DHLP-2 have been introduced. Biological networks are one type
of the heterogeneous complex networks. As a case study, we have measured the
efficiency of our proposed DHLP-1 and DHLP-2 algorithms on a biological network
consisting of drugs, diseases, and targets. The subject we have studied in this
network is drug repositioning but our algorithms can be used as general methods
for heterogeneous networks other than the biological network. Results: We
compared the proposed algorithms with similar non-distributed versions of them
namely MINProp and Heter-LP. The experiments revealed the good performance of
the algorithms in terms of running time and accuracy.Comment: Source code available for Apache Giraph on Hadoo
Drug repurposing using biological networks
Drug repositioning is a strategy to identify new uses for existing, approved, or research drugs that are outside the scope of its original medical indication. Drug repurposing is based on the fact that one drug can act on multiple targets or that two diseases can have molecular similarities, among others. Currently, thanks to the rapid advancement of high-performance technologies, a massive amount of biological and biomedical data is being generated. This allows the use of computational methods and models based on biological networks to develop new possibilities for drug repurposing. Therefore, here, we provide an in-depth review of the main applications of drug repositioning that have been carried out using biological network models. The goal of this review is to show the usefulness of these computational methods to predict associations and to find candidate drugs for repositioning in new indications of certain diseases
Predicting potential drugs and drug-drug interactions for drug repositioning
The purpose of drug repositioning is to predict novel treatments for existing drugs. It saves time and reduces cost in drug discovery, especially in preclinical procedures. In drug repositioning, the challenging objective is to identify reasonable drugs with strong evidence. Recently, benefiting from various types of data and computational strategies, many methods have been proposed to predict potential drugs.
Signature-based methods use signatures to describe a specific disease condition and match it with drug-induced transcriptomic profiles. For a disease signature, a list of potential drugs is produced based on matching scores. In many studies, the top drugs on the list are identified as potential drugs and verified in various ways. However, there are a few limitations in existing methods: (1) For many diseases, especially cancers, the tissue samples are often heterogeneous and multiple subtypes are involved. It is challenging to identify a signature from such a group of profiles. (2) Genes are treated as independent elements in many methods, while they may associate with each other in the given condition. (3) The disease signatures cannot identify potential drugs for personalized treatments.
In order to address those limitations, I propose three strategies in this dissertation. (1) I employ clustering methods to identify sub-signatures from the heterogeneous dataset, then use a weighting strategy to concatenate them together. (2) I utilize human protein complex (HPC) information to reflect the dependencies among genes and identify an HPC signature to describe a specific type of cancer. (3) I use an HPC strategy to identify signatures for drugs, then predict a list of potential drugs for each patient.
Besides predicting potential drugs directly, more indications are essential to enhance my understanding in drug repositioning studies. The interactions between biological and biomedical entities, such as drug-drug interactions (DDIs) and drug-target interactions (DTIs), help study mechanisms behind the repurposed drugs. Machine learning (ML), especially deep learning (DL), are frontier methods in predicting those interactions. Network strategies, such as constructing a network from interactions and studying topological properties, are commonly used to combine with other methods to make predictions. However, the interactions may have different functions, and merging them in a single network may cause some biases. In order to solve it, I construct two networks for two types of DDIs and employ a graph convolutional network (GCN) model to concatenate them together.
In this dissertation, the first chapter introduces background information, objectives of studies, and structure of the dissertation. After that, a comprehensive review is provided in Chapter 2. Biological databases, methods and applications in drug repositioning studies, and evaluation metrics are discussed. I summarize three application scenarios in Chapter 2.
The first method proposed in Chapter 3 considers the issue of identifying a cancer gene signature and predicting potential drugs. The k-means clustering method is used to identify highly reliable gene signatures. The identified signature is used to match drug profiles and identify potential drugs for the given disease. The second method proposed in Chapter 4 uses human protein complex (HPC) information to identify a protein complex signature, instead of a gene signature. This strategy improves the prediction accuracy in the experiments of cancers. Chapter 5 introduces the signature-based method in personalized cancer medicine. The profiles of a given drug are used to identify a drug signature, under the HPC strategy. Each patient has a profile, which is matched with the drug signature. Each patient has a different list of potential drugs. Chapter 6 propose a graph convolutional network with multi-kernel to predict DDIs. This method constructs two DDI kernels and concatenates them in the GCN model. It achieves higher performance in predicting DDIs than three state-of-the-art methods.
In summary, this dissertation has proposed several computational algorithms for drug repositioning. Experimental results have shown that the proposed methods can achieve very good performance
Integrative methods for analyzing big data in precision medicine
We provide an overview of recent developments in big data analyses in the context of precision medicine and health informatics. With the advance in technologies capturing molecular and medical data, we entered the area of “Big Data” in biology and medicine. These data offer many opportunities to advance precision medicine. We outline key challenges in precision medicine and present recent advances in data integration-based methods to uncover personalized information from big data produced by various omics studies. We survey recent integrative methods for disease subtyping, biomarkers discovery, and drug repurposing, and list the tools that are available to domain scientists. Given the ever-growing nature of these big data, we highlight key issues that big data integration methods will face
Integrative methods for analysing big data in precision medicine
We provide an overview of recent developments in big data analyses in the context of precision medicine and health informatics. With the advance in technologies capturing molecular and medical data, we entered the area of “Big Data” in biology and medicine. These data offer many opportunities to advance precision medicine. We outline key challenges in precision medicine and present recent advances in data integration-based methods to uncover personalized information from big data produced by various omics studies. We survey recent integrative methods for disease subtyping, biomarkers discovery, and drug repurposing, and list the tools that are available to domain scientists. Given the ever-growing nature of these big data, we highlight key issues that big data integration methods will face
- …